526 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B N/A
Article Searches
Top Stock Reports for Visa, JPMorgan & Bank of America http://www.zacks.com/research-daily/777118/top-stock-reports-for-visa-jpmorgan-bank-of-america?cid=CS-ZC-FT-research_daily-777118 Feb 21, 2020 - Top Stock Reports for Visa, JPMorgan & Bank of America
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval http://www.zacks.com/stock/news/777121/pharma-stock-roundup-azn-reports-q4-results-nvs-pfe-drugs-get-eu-approval?cid=CS-ZC-FT-analyst_blog|stock_roundup-777121 Feb 21, 2020 - AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review http://www.zacks.com/stock/news/775823/roches-tecentriq-sbla-for-lung-cancer-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-775823 Feb 20, 2020 - Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.
AstraZeneca's (AZN) CEO Pascal Soriot on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4324488-astrazenecas-azn-ceo-pascal-soriot-on-q4-2019-results-earnings-call-transcript?source=feed_sector_healthcare Feb 14, 2020 - AstraZeneca PLC (NYSE:AZN) Q4 2019 Earnings Conference Call February 14, 2020 7:00 AM ET Company Participants Pascal Soriot – Chief Executive Officer Dave Fredrickson – Executive Vice President, Oncol
AstraZeneca PLC (AZN) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/02/14/astrazeneca-plc-azn-q4-2019-earnings-call-transcri.aspx?source=iedfolrf0000001 Feb 14, 2020 - AZN earnings call for the period ending December 31, 2019.
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study http://www.zacks.com/stock/news/763946/mercks-keytruda-meets-pfs-endpoint-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-763946 Feb 13, 2020 - Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
FibroGen's Anemia Drug Goes to FDA for Review https://www.fool.com/investing/2020/02/12/fibrogens-anemia-drug-goes-to-fda-for-review.aspx?source=iedfolrf0000001 Feb 12, 2020 - A decision on Roxadustat should arrive by Dec. 20.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA http://www.zacks.com/stock/news/761981/fibrogens-fgen-nda-for-roxadustat-accepted-by-the-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-761981 Feb 12, 2020 - The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
What's in Store for AstraZeneca (AZN) This Earnings Season? http://www.zacks.com/stock/news/760054/whats-in-store-for-astrazeneca-azn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-760054 Feb 11, 2020 - AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
What's in Store for Ironwood (IRWD) This Earnings Season? http://www.zacks.com/stock/news/758462/whats-in-store-for-ironwood-irwd-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-758462 Feb 10, 2020 - Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

Pages: 123456...53

Page 1>